Humana Inc. HUM
Verdict: Sell. Fair value $228 against a price of $276 on 6 Jan 2026, 17% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Net Income collapsed by over 51% from $2.49B in 2023 to $1.21B in 2024. This continues a multi-year.... In 2024, Operating Cash Flow ($2.97B) was 246% of Net Income ($1.21B). While strong cash flow is....
Main risks
- Collapsing Profitability: Net income and margins are in a steep multi-year decline. Annual net income has fallen from $2.93B in 2021 to $1.21B in 2024, and the TTM operating margin (proxy) is below 1%.
- Negative Return on Incremental Capital: A 3-year ROIIC of -17.0% is a severe red flag, indicating that the ~$10B in capital deployed over the last three years has destroyed value by reducing operating profit.
- High Financial Leverage: The estimated Net Debt/EBITDA ratio is over 5.7x (assuming zero cash). This level suggests a high degree of financial risk, which is particularly concerning given the company's deteriorating profitability.
- Net Income collapsed by over 51% from $2.49B in 2023 to $1.21B in 2024. This continues a multi-year...
- In 2024, Operating Cash Flow ($2.97B) was 246% of Net Income ($1.21B). While strong cash flow is...
- Intense competitive environment